For instance, CB1/CB2 agonists may interrupt excitotoxicity and reduce neuroinflammation in AD brains, modulators of endocannabinoid signaling may reduce hyperactivity in HD, while CB1 agonists could reduce dyskinesia in PD. Here, CNR2 is linked to drug-induced dyskinesia.